In a recent press release, Radient Technologies Inc. announced that one of their product lines would be available to patients participating in the University Health Network (UHN, Toronto, Canada) Medical Cannabis Real-World Evidence Study (MC-RWE Study) in partnership with Medical Cannabis by Shoppers.
In a recent press release (1), Radient Technologies Inc. announced that one of their product lines would be available to patients participating in the University Health Network (UHN, Toronto, Canada) Medical Cannabis Real-World Evidence Study (MC-RWE Study) in partnership with Medical Cannabis by Shoppers. The first-of-its-kind study aims to explore the effects of medical cannabis relating on the topics of pain, sleep, and anxiety issues in a nation-wide clinical trial in Canada that will be led by UHN’s Dr. Hance Clarke (2).
Radient is a high-quality cannabinoid-based formulations and products manufacturer and their bioU brand was designed exclusively for Medical Cannabis by Shoppers. The three oral spray formulations will be made available to the MC-RWE Study participants. Radient’s bioU line reportedly offers patients a variety of tetrahydrocannabinol (THC) and cannabidiol (CBD) products in a convenient standard dose format. To be used in the study, the bioU products had to undergo further testing where the cannabinoid and terpene profile results were registered on TruTrace Technologies software platform and integrated with the Medical Cannabis by Shoppers.
“Radient strongly believes that consistency, safety, and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers, and TruTrace on this groundbreaking study,” said Denis Taschuk, the CEO of Radient Technologies said (1). “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products. Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes.”
The Medical Cannabis Real-World Evidence Study will take place over a 24-week period and involve a minimum of 2000 patients in the research program.
“The challenge with the medical use of cannabis is that physicians and patients are unsure of the quality of products being consumed,” said Dr. Clarke, Director of Pain Services, Toronto General Hospital (TGH) (2). “For the first time we will have a national repository of data that can provide answers about the effectiveness of these products, to test their claims.”
With this research, quality standards will be ensured, allowing physicians and patients to be confident in using medical cannabis to treat their pain-related ailments.
Credit: Source link